Breaking News Instant updates and real-time market news.

CLVS

Clovis

$25.19

0.31 (1.25%)

07:08
02/13/19
02/13
07:08
02/13/19
07:08

Clovis initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Edward White started Clovis Oncology with a Buy rating and $40 price target. Investors are missing the potential opportunity that the PARP market holds in ovarian cancer and other indications, White tells investors in a research note. While penetration of the PARP market has been slow, investors are not giving Clovis enough credit for the potential size of the market, says the analyst. He believes the size of the monotherapy ovarian cancer PARP market "has plenty of room to expand."

  • 26

    Feb

CLVS Clovis
$25.19

0.31 (1.25%)

12/04/18
LEER
12/04/18
UPGRADE
LEER
Outperform
Clovis upgraded to Outperform from Market Perform at Leerink
12/04/18
12/04/18
UPGRADE
Target $40

Outperform
Clovis upgraded to Outperform after favorable EU patent ruling at Leerink
As previously reported, Leerink analyst Andrew Berens upgraded Clovis Oncology (CLVS) to Outperform from Market Perform after the European Patent Office upheld claims of a European patent on Rubraca. He said the finding of inventiveness in Europe strengthens his confidence in the U.S. patent estate and removes a near-term intellectual property overhang on Clovis shares. Berens now sees a 50% chance of branded exclusivity through 2023 in the U.S. in the "worst case" and through 2031 in the "best case." He also said Glaxo's (GSK) acquisition of competitor Tesaro (TSRO) brings a "return of optionality" to Clovis shares. Berens raised his price target on Clovis to $40 from $22.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
12/14/18
LEER
12/14/18
NO CHANGE
LEER
Outperform
Tesaro proxy documents point to interest in PARP economics, says Leerink
Leerink analyst Andrew Berens noted that GlaxoSmithKline (GSK) and Tesaro (TSRO) disclosed background details for their deal agreement in a filing this morning. The documents show several parties were interested in a strategic transaction with Tesaro at various points over the last year, though the strategic interest appears to have been driven by Glaxo and one additional company, identified as "Party A", Berens said. It is not clear why the six other contacted parties were not interested in pursuing a strategic transaction, but he thinks Party A's co-promote proposal and the initial interest of other potential acquirers indicates strategic interest in the economics surrounding a PARP. Berens, who continues to see Clovis (CLVS) being well-positioned as the remaining stand-alone PARP-focused company, keeps an Outperform rating on Clovis and Market Perform rating on Tesaro.

TODAY'S FREE FLY STORIES

ET

Energy Transfer LP

$15.51

-0.13 (-0.83%)

16:22
02/20/19
02/20
16:22
02/20/19
16:22
Hot Stocks
Breaking Hot Stocks news story on Energy Transfer LP »

Energy Transfer LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

O

Realty Income

$68.81

-1.145 (-1.64%)

16:22
02/20/19
02/20
16:22
02/20/19
16:22
Earnings
Realty Income reports Q4 AFFO 79c, consensus 75c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

KRO

Kronos Worldwide

$15.46

0.56 (3.76%)

16:22
02/20/19
02/20
16:22
02/20/19
16:22
Hot Stocks
Kronos Worldwide increases quarterly dividend by 1c per share »

Kronos Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHE

Chemed

$316.62

1.32 (0.42%)

16:22
02/20/19
02/20
16:22
02/20/19
16:22
Earnings
Chemed sees 2019 adjusted EPS $12.65-$12.85, consensus $12.54 »

Revenue growth for VITAS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

TRN

Trinity Industries

$25.98

0.38 (1.48%)

16:22
02/20/19
02/20
16:22
02/20/19
16:22
Earnings
Trinity Industries sees FY19 EPS $1.15-$1.35, consensus $1.28 »

Sees net lease fleet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 26

    Mar

ET

Energy Transfer LP

$15.51

-0.13 (-0.83%)

16:22
02/20/19
02/20
16:22
02/20/19
16:22
Earnings
Energy Transfer LP reports Q4 EPS 26c, consensus 34c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

INOV

Inovalon

$15.42

0.49 (3.28%)

16:21
02/20/19
02/20
16:21
02/20/19
16:21
Earnings
Inovalon reports Q4 EPS 5c, consensus 9c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

CHE

Chemed

$316.62

1.32 (0.42%)

16:21
02/20/19
02/20
16:21
02/20/19
16:21
Earnings
Chemed reports Q4 adjusted EPS $3.35, consensus $3.26 »

Reports Q4 revenue $458M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

TRN

Trinity Industries

$25.98

0.38 (1.48%)

16:21
02/20/19
02/20
16:21
02/20/19
16:21
Earnings
Trinity Industries reports Q4 EPS 19c, consensus 25c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 26

    Mar

XEC

Cimarex Energy

$76.38

1.3 (1.73%)

16:21
02/20/19
02/20
16:21
02/20/19
16:21
Hot Stocks
Cimarex Energy reports Q4 volumes averaged 251.3 MBOE per day »

Driven by solid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 04

    Mar

  • 22

    May

QEP

QEP Resources

$8.19

-0.08 (-0.97%)

16:21
02/20/19
02/20
16:21
02/20/19
16:21
Earnings
QEP Resources reports Q4 EPS ($2.66), may not compare to consensus 3c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NAVI

Navient

$12.65

-0.15 (-1.17%)

16:21
02/20/19
02/20
16:21
02/20/19
16:21
Hot Stocks
Canyon Partners withdraws Navient indication of interest, to propose board slate »

Canyon Capital Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPTN

SpartanNash

$21.98

-0.25 (-1.12%)

16:21
02/20/19
02/20
16:21
02/20/19
16:21
Earnings
SpartanNash sees FY19 EPS $1.70-$1.80, consensus $1.93 »

Sees FY19 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SUN

Sunoco

$29.86

-0.42 (-1.39%)

16:20
02/20/19
02/20
16:20
02/20/19
16:20
Earnings
Sunoco reports Q4 EPS ($1.11), may not compare to consensus 73c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

XEC

Cimarex Energy

$76.38

1.3 (1.73%)

16:20
02/20/19
02/20
16:20
02/20/19
16:20
Earnings
Cimarex Energy reports Q4 adjusted EPS $1.98, consensus $1.80 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 04

    Mar

  • 22

    May

TYL

Tyler Technologies

$213.19

-2.55 (-1.18%)

16:20
02/20/19
02/20
16:20
02/20/19
16:20
Earnings
Tyler Technologies sees FY19 adjusted EPS $5.20-$5.35, consensus $5.37 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
02/20/19
02/20
16:20
02/20/19
16:20
Options
Closing CBOE SPX and VIX Index summary for February 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$24.56

0.61 (2.55%)

16:19
02/20/19
02/20
16:19
02/20/19
16:19
Hot Stocks
TechnipFMC estimates $280M settlement for global anticorruption investigations »

TechnipFMC said in its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 04

    Mar

NAVI

Navient

$12.65

-0.15 (-1.17%)

16:19
02/20/19
02/20
16:19
02/20/19
16:19
Hot Stocks
Breaking Hot Stocks news story on Navient »

Canyon Partners to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYL

Tyler Technologies

$213.19

-2.55 (-1.18%)

16:19
02/20/19
02/20
16:19
02/20/19
16:19
Earnings
Tyler Technologies reports Q4 adjusted EPS $1.26, consensus $1.26 »

Reports Q4 revenue $242M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

AXTI

AXT Inc.

$4.50

0.13 (2.97%)

16:19
02/20/19
02/20
16:19
02/20/19
16:19
Hot Stocks
AXT Inc. CEO says 2018 a 'mixed year' »

"2018 was a mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

NAVI

Navient

$12.65

-0.15 (-1.17%)

16:19
02/20/19
02/20
16:19
02/20/19
16:19
Hot Stocks
Breaking Hot Stocks news story on Navient »

Canyon Partners withdraws…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPTN

SpartanNash

$21.98

-0.25 (-1.12%)

16:18
02/20/19
02/20
16:18
02/20/19
16:18
Earnings
SpartanNash reports Q4 adjusted EPS 32c, consensus 38c »

Reports Q revenue $1.90B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

FTI

TechnipFMC

$24.56

0.61 (2.55%)

16:18
02/20/19
02/20
16:18
02/20/19
16:18
Earnings
TechnipFMC sees 2019 Subsea revenue $5.4B-$5.7B »

Sees 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 04

    Mar

AXTI

AXT Inc.

$4.50

0.13 (2.97%)

16:18
02/20/19
02/20
16:18
02/20/19
16:18
Earnings
AXT Inc. reports Q4 EPS (3c), consensus 0c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.